Treatment of relapsed and/or refractory langerhans cell histiocytosis

Histiocytic Disorders of Children and Adults

Volumn , Issue , 2005, Pages 254-271

  Weitzman, Sheila ^a   L Mc Clain, Kenneth ^b   Arceci, Robert ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928298641     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545252.014     Document Type: Chapter

References (101)

1. Akkari, V., Donadieu, J., Piguet, C., et al. (2003). Hematopoietic stem cell transplantation in patients with Langerhans cell histiocytosis and hematological dysfunction. Experience of the French Langerhans Cell Study Group. Bone Marrow Transplant,31, 1097-1103.
2. Amrolia, P., Caspar, H.B., Hassan, A., et al. (2000). Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood,96, 1239-1246.
3. Arceci, R.J., Brenner, M.K. and Pritchard, J. (1998). Controversies and new approaches to treatment of LCH. Hematol Oncol Clin North Am,12, 339-357.
4. Arico, M. (1991). Cyclosporine therapy for refractory Langerhans cell histiocytosis. Blood,78, 3107-3110.
5. Ayas, M., Mustafa, M., Al-Mahr, M., et al. (1998). Bone marrow transplantation for refractory disseminated Langerhans histiocytosis. Proceedings of the XIV Meeting Histiocyte Society, Kyoto, 36.
6. Bernard, F., Thomas, C., Chiron, C., et al. (2003). Association between 2-CdA and Ara-C as a rescue for pediatric patients with LCH-hematological dysfunction and failure to standard therapy. Proceedings of the XIX Meeting Histiocyte Society, Philadelphia, 31.
7. Braier, J., Cioccca, M., Latella, A., et al. (2002). Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol,38, 178-182.
8. Brewer, C.J., Ullenbruch, M.R., Dick, R., et al. (2003). Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med,14,210-216.
9. Broadbent, V. and Ladisch, S. (1997). Results of the Histiocyte Society BMT salvage questionnaire. Med Pediatr Oncol,31,45.
10. Brown, R.E. (2001). Bisphosphonates as antialveolar macrophage therapy in pulmonary Langerhans cell histiocytosis. Med Pediatr Oncol,36, 641-643.
11. Burdmann, E.A., Andoh, T.F., Yu, L., et al. (2003). Cyclosporine nephrotoxicity. Semin Nephrol,23, 465-476.
12. Ceci, A., de Terlizzi, M., Colella, R., et al. (1988a). Etoposide in recurrent childhood Langerhans’ cell histiocytosis: an Italian cooperative study. Cancer,62,2528-2531.
13. Ceci, A., de Terlizzi, M., Toma, M.C., et al. (1988b). Heterogeneity of immunological patterns in Langerhans cell histiocytosis and response to crude thymic extract in 11 patients. Med Pediatr Oncol,16, 111-115.
14. Chang, S.E., Koh, C.J., Choi, J.H., et al. (2002). Widespread skin-limited adult Langerhans cell histiocytosis: long term follow up with good response to interferon alpha. Clin Exp Dermatol, 27, 135-137.
15. Charles, P., Elliot, M.J., Davis, D., et al. (1999). Regulation of cytokines, cytokine inhibitors and acute phase proteins following anti-TNFa therapy in rheumatoid arthritis. J Immunol,163,1521-1528.
16. Cheson, B., Vena, D.A., Barrett, J., et al. (1999). Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemia. J Clin Oncol,13,2454-2464.
17. Choi, S.W., Bangaru, B.S., Wu, C.D., et al. (2003). Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadeno- sine and high-dose cytarabine. J Pediatr Hematol Oncol,25, 503-506.
18. Chubar, Y. and Bennett, M. (2003). Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Br J Haematol,122, 768-770.
19. Claudon, A., Dietamann, J.L., Hamman, D.C.A., et al. (2002). Interest in thalidomide in cutaneo- mucous and hypothalamo-hypophyseal involvement of Langerhans cell histiocytosis. Rev Med Interne,23, 651-656.
20. Cole, S. and Finlay, J. (1999). 2-Chlorodeoxyadenosine for adults with multi-system Langerhans cell histiocytosis. Med Pediatr Oncol,33, 512.
21. Conter, V., Reciputo, A., Arrigo, C., et al. (1996). Bone marrow transplantation for refractory Langerhans cell histiocytosis. Hematologica,81,468-471.
22. Crews, K.R., Gandhi, V., Srivastava, D.K., et al. (2002). Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol,20, 4217-4224.
23. Culic, S., Jakobson, A., Culik, V., et al. (2001). Etoposide as the basic and interferon - as the maintenance therapy for Langerhans cell histiocytosis: a RTC. Pediatr Hematol Oncol, 18, 291-294.
24. Debray, D. (2003). Sclerosing cholangitis in children: an overview. Proceeding of XIX Meeting Histiocyte Society, Philadelphia, 17.
25. Dimopoulos, M.A., Theodorakis, M., Kostis, E., et al. (1996). Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leukemia lymphoma,25, 187-189.
26. Dredge, K., Marriott, J.B. and Dalgleish, A.G. (2002). Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol,22, 425-437.
27. Egeler, R.M., de Kraker, J. and Voute, P.A. (1993). Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol,21,265-270.
28. Egeler, R.M., Anderson, R.A., Wolff, J.E.A., et al. (1998). Allogeneic peripheral blood stem cell transplantation in Langerhans cell histiocytosis. Proceeding of XIVth Meeting Histiocyte Society, Kyoto, Japan, 34.
29. Egeler, R.M., Favara, B.E., van Meurs, M., et al. (1999). Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treament. Blood,94,4195-4201.
30. Etienne, B., Bertocchi, M., Gamondes, J.-P., et al. (1998). Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Resp Crit Care Med,157, 288-291.
31. Felix, C.A. and Blatt, J. (1999). Etoposide and Langerhans cell histiocytosis: second malignancies, a second look. Pediatr Hematol Oncol,16, 183-185.
32. Frost, J.D. and Wiersma, S.R. (1996). Langerhans cell histiocytosis in an infant with Klinefelters syndrome successfully treated with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol,18, 396-400.
33. Gadner, H., Grois, N., Arico, M., et al. (2001). A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr,138, 728-734.
34. Gadner, H., Matthes-Martin, S., Grois, N., et al. (2002). Stem cell transplantation (SCT) with reduced intensity conditioning - a possible salvage strategy for high risk Langerhans cell histiocytosis. Med Pediatr Oncol, 38, 222.
35. Gandhi, V., Estey, E., Keating, M.J., et al. (1996). Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood,87,256-264.
36. Geissmann, F., Landman-Parker, J., Thomas, C., et al. (1997). In vitro effects of retinoic acid on Langerhans cell histiocytosis cells and normal dendritic cells. Med Pediatr Oncol,31,49.
37. Giona, F., Annino, L., Bongarzoni, V., et al. (2002). Unifocal Langerhans’ cell histiocytosis involving the central nervous system successfully treated with 2-chlorodeoxyadenosine. Med Pediatr Oncol, 38, 223.
38. Goh, N.S., McDonald, C.E., Macgregor, D.P., et al. (2003). Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Respirology,8, 91-94.
39. Greinix, H.T., Storb, R., Sanders, J.E., et al. (1992). Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis. Bone Marrow Transplant,10, 39-44.
40. Groh, V., Gadner, H., Radaszkiewicz, T., et al. (1988). The phenotypic spectrum of histiocytosis X cells. J Invest Dermatol,90, 441-447.
41. Habib, S.B., Congleton, J., Carr, D., et al. (1998). Recurrence of recipient Langerhans cell histiocytosis following bilateral lung transplantation. Thorax,53, 323-325.
42. Hadzic, N., Pritchard, J., Webb, D., et al. (2000). Recurrence of Langerhans cell histiocytosis in the graft after pediatric liver transplantation. Transplantation,15, 815-819.
43. Hale, G.A., Bowman, L.C., Woodard, J.P., et al. (2003). Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant,31, 981-986.
44. Helmbold, P., Hegemann, B., Holzhausen, H.-J., et al. (1998). Low dose oral etoposide monotherapy in adult Langerhans cell histiocytosis. Arch Dermatol,134, 1275-1278.
45. Henter, J.-I., Karlen, J., Calming, U., et al. (2001). Successful treatment of Langerhans’-cell histiocytosis with Etanercept. New Engl J Med, 345, 1577-1578.
46. Hirose, M. and Kuroda, Y. (1999). Successful induction therapy of natural killer/cytotoxic T-lymphocyte cells in the treatment of Langerhans’ cell histiocytosis. Int JHematol,69,272-273.
47. Johnston, J.B., Williams, M., Verburg, L., et al. (1993). Combined therapy with deoxyadenosine plus 2'-deoxycoformycin and alkylating agents. Proc Annu Meet AACR,34, A1765.
48. Joshi, S., Parisi, M., Smogorzevska, E., et al. (1999). Long term immune deficiency in a patient with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine. Med Pediatr Oncol, 33, 523.
49. Kelly, K.M. and Pritchard, J. (1994).Monoclonal antibody therapy in Langerhans cell histiocytosis- feasible and reasonable? Br J Cancer,23(Suppl), S54-S55.
50. Kelly, M., Kolb, M., Bonniaud, et al. (2003). Re-evaluation of fibrogenic cytokines in lung fibrosis. Current Pharm Design, 9, 39-49.
51. Kinugawa, N., Imashuku, S., Hirota, Y., et al. (1999). Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan. Bone Marrow Transplant,24,935-938.
52. Korholz, D., Janssen, G. and Gobel, U. (1997). Treatment of relapsed Langerhans cell histiocytosis by cyclosporin A combined with etoposide and prednisone. Pediatr Hematol Oncol,14,443-449.
53. Kwong, Y.L., Chan, A.C.L. and Chan, T.K. (1997). Widespread skin-limited Langerhans cell histiocytosis: complete remission with interferon alfa. J Am Acad Dermatol,36, 628-629.
54. Ladisch, S. and Gadner, H. (1994). Treatment of Langerhans cell histiocytosis - evolution and current approaches. Br J Cancer,70(Suppl XXIII), S41-S46.
55. Ladisch, S., Gadner, H., Arico, M., et al. (1994). A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol,23, 107-110.
56. Lair, G., Marie, I., Cailleux, N., et al. (1998). Langerhans cell histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide. Rev Med Interne,19,196-198.
57. Liliemark, J. (1997). The clinical pharmacokinetics of cladribine. Clin Pharmacokinet,32,120-131.
58. Lombardi, A., Caniglia, M., Longo, D., et al. (2002). Treatment of severe Langerhans cell histiocytosis with 2' deoxycoformycin (2'-DCF). Hematol J,3, 118-119.
59. Mahe, E., Descamps, V., Grossin, M., et al. (2003). CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab. Br J Dermatol,149, 170-173.
60. Mahmoud, H., Wang, W. and Murphy, S. (1991). Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood,77, 721-725.
61. Marti, L., Thomas, C., Emile, J.F., et al. (2003). Liver involvement in LCH. The French experience. Proceedings of the XIX Meeting Histiocyte Society, Philadelphia, 20.
62. Matsushima, Y. and Baba, T. (1991). Resolution of cutaneous lesions of histiocytosis-X by intralesional injections of interferon-beta. Int J Dermatol,30, 373-374.
63. McCowage, G.B., Frush, D.P. and Kurtzberg, J. (1996). Successful treatment of two children with Langerhans cell histiocytosis with 2'-deoxycoformycin. JPediatr Hematol Oncol,18, 154-158.
64. Minkov, M., Grois, N., Broadbent, V., et al. (1999). Cyclosporine A therapy for multisystem Langerhans cell histiocytosis. Med Pediatr Oncol, 33, 482-485.
65. Minkov, M.L., Novichkova, L.A., Maschan, A.A., et al. (2001). Retinoic acid and alfa-interferon in poor prognosis Langerhans cell histiocytosis (LCH). Med Pediatr Oncol,31,46.
66. Minkov, M., Grois, N., Heitger, A., et al. (2002). Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol,39,581-585.
67. Misery, L., Larbre, B., Lyonnet, S., et al. (1993). Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol,18,487.
68. Montero, A.J., Diaz-Montero, C.M., Malpica, A., et al. (2003). Langerhans cell histiocytosis of the female genital tract: a literature review. Int J Gynecol Cancer,13, 381-388.
69. Moraes, M. and Russo, G. (2001). Thalidomide and it’s dermatologic uses. Am J Med Sci,321, 321-326.
70. Mortazavi, H., Ehsani, A., Namazi, M.R., et al. (2002). Langerhans’ cell histiocytosis. Dermatol Online J, 8, 18.
71. Murray, S., Rowlinson-Busza, G., Morris, J.F., et al. (2000). Diagnostic and therapeutic evaluation of an anti-Langerhans cell histiocytosis monoclonal antibody (NA1/34) in a new xenograft model. J Invest Dermatol,114, 127-134.
72. Nagarajan, R., Neglia, J., Ramsay, N., et al. (2001). Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation. J Pediatr Hematol Oncol,23, 629-632.
73. Newell, K.A., Alonso, E.M., Kelly, S.M., et al. (1997). Association between liver transplantation for Langerhans cell histiocytosis, rejection and development of posttransplantation lympho- proliferative disease in children. J Pediatr,131, 98-104.
74. Noseworthy, M., Odame, I., Doda, W., et al. (2003). Pulmonary Langerhans cell histiocytosis - a variable disease in childhood. Med Pediatr Oncol,40, 180.
75. Osband, M.E., Lipton, J.M., Lavin, O., et al. (1981). Histiocytosis X: demonstration of abnormal immunity, T-cell histamine H2 receptor deficiency, and successful treatment with thymic extract. New Engl J Med,304, 146-153.
76. Ottaviano, F. and Finlay, J.L. (2003). Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol,25, 575-577.
77. Pardanani, A., Phyliky, R.L., Li, C.-Y., et al. (2003). 2-Chloro-deoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc,78, 301-306.
78. Perreault, C., Pelletier, M., Landry, D., et al. (1984). Study of Langerhans cells after allogeneic bone marrow transplantation. Blood,63, 807-811.
79. Rajwal, S.R., Stringer, M.D., Davison, S.M., et al. (2003). Use of basiliximab in pediatric liver transplantation for Langerhans cell histiocytosis. Pediatr Transplant,7, 247-251.
80. Ringden, O., Ahstrom, L., Lonnqvist, B., et al. (1987). Allogeneic bone marrow transplantation in a patient with chemotherapy resistant progressive histiocytosis-X. New Engl J Med,316, 733-735.
81. Ringden, O., Lonnqvist, B. and Holst, M. (1997). 12-year follow-up of allogeneic bone-marrow transplant for Langerhans’ cell histiocytosis. Lancet,349, 476.
82. Robak, T., Blonski, J.Z., Kasznicki, M., et al. (2002). Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J, 244-250.
83. Rodriguez-Galindo, C., Kelly, P., Jeng, M., et al. (2002). Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol,69, 179-184.
84. Sako, M., Hosoi, G., Ikemiya, M., et al. (1999). Successful remission induction in a case of disseminated and refractory Langerhans cell histiocytosis (LCH) with a combination of cyclosporin (CSA) plus multiagent chemotherapy (ACOP). Med Pediatr Oncol,33, 521.
85. Santana, V.M., Mirro, J., Harwood, F.C., et al. (1991). A phase 1 clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol,9, 416-422.
86. Saven, A. and Burian, C. (1999). Cladribine activity in adult Langerhans cell histiocytosis. Blood, 93,4125-4130.
87. Saven, A., Foon, K. and Piro, L. (1994). 2-Chlorodeoxyadenosine induced complete remissions in Langerhans cell histiocytosis. Ann Intern Med,21,430-432.
88. Schwartz, J.E. and Yeager, A.M. (2003). Reduced-intensity allogeneic hematopoietic cell transplantation: graft versus tumor effects with decreased toxicity. Pediatr Transplant,7, 168-178.
89. Smith, M.A., Rubenstein, L., Anderson, J.R., et al. (1999). Secondary leukemia or myelodysplas- tic syndrome after treatment with epipodophyllotoxins. J Clin Oncol,17, 569-577.
90. Soler, P., Bergeron, A., Kambouchner, M., et al. (2000). Is high resolution computed tomography a reliable tool to predict the histopathological activity of pulmonary Langerhans cell histiocytosis. Am J Resp Crit Care Med,162, 264-270.
91. Stieber, A.C., Sever, C. and Starzl, T.E. (1990). Liver transplantation in patients with Langerhans’ cell histiocytosis. Transplantation,50, 338-340.
92. Stine, K.C., Saylors, R.L., Willimas, L.L., et al. (1997). 2-Chlorodeoxyadenosine (2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol, 29, 288-292.
93. Stoll, M., Freund, M., Schmid, H., et al. (1990). Allogeneic bone marrow transplantation for Langerhans cell histiocytosis. Cancer,66, 284-288.
94. Strieter, R.M. (2003). Mechanisms of pulmonary fibrosis - conference summary. Chest, 120(Suppl), 77S-85S.
95. Suminoe, A., Matsuzaki, A., Hattori, H., et al. (2001). Unrelated cord blood transplantation for an infant with chemotherapy resistant progressive Langerhans cell histiocytosis. J Pediatr Hematol Oncol, 23, 633-666.
96. Sundar, K.M., Gosselin, M.V., Chung, H.L., et al. (2003). Pulmonary Langerhans cell histiocytosis. Emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest,123, 1673-1683.
97. The French LCH Study Group (1996). A multicentre retrospective survey of LCH: 348 cases observed between 1983 and 1993. Arch Dis Child,75, 17-24.
98. Vassallo, R., Ryu, J.H., Schroeder, D.R., et al (2002). Clinical outcomes of pulmonary Langerhans’- cell histiocytosis in adults. New Engl J Med,346, 484-490.
99. Watts, J. and Files, B. (2001). Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol,18, 199-204.
100. Weitzman, S., Wayne, A.S., Arceci, R., et al. (1999). Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the Histiocyte Society and review of the literature. Med Pediatr Oncol,33,476-481.
101. Woltman, A.M., de Fijter, J.W., Kamerling, S.W.A., et al. (2001). Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood, 98, 174-180.